Prilenia: Clinical Trials

10 trials sponsored by Prilenia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 recruiting, 2 terminated, 1 no longer available. 5 Phase 2, 4 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Terminated 2
Phase 34Completed 2, Recruiting 2
Phase 11Completed 1

Follow Prilenia: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pridopidine Phase 3 Study in Huntington's Disease
Pridopidine, Placebo - Huntington Disease
Phase 3RecruitingPrilenia4002026-07-012026-11-19
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Pridopidine, Placebo - Amyotrophic Lateral Sclerosis
Phase 3RecruitingPrilenia5002026-02-012026-11-17
HEALEY ALS Platform Trial - Regimen D Pridopidine
Pridopidine, Matching Placebo - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3CompletedMerit E. Cudkowicz, MD1632020-12-182023-08-23
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Pridopidine, Placebo - Huntington Disease
Phase 3CompletedPrilenia4992020-10-162025-03-12
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
Pridopidine, Placebo - Parkinson Disease
Phase 2TerminatedPrilenia232019-05-222022-07-01
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
pridopidine (90 mg) - Health Volunteers, Huntington Disease
Phase 1CompletedPrilenia232017-04-192021-11-19
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
Pridopidine - Huntington's Disease
Phase 2TerminatedPrilenia2482015-09-242021-09-17
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Pridopidine, Placebo - Huntington's Disease
Phase 2CompletedPrilenia4082014-02-282021-07-19
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
pridopidine - Huntington Disease
Phase 2CompletedPrilenia1342011-03-242022-02-09
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
Pridopidine - Amyotrophic Lateral Sclerosis
No longer availablePrilenia2025-05-18

Conditions studied

Huntington Disease (6)  ·  Amyotrophic Lateral Sclerosis (3)  ·  Dyskinesias (2)  ·  Basal Ganglia Diseases (1)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Cognition Disorders (1)  ·  Dementia (1)  ·  Heredodegenerative Disorders, Nervous System (1)  ·  Mental Disorders (1)  ·  Movement Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurocognitive Disorders (1)  ·  Neurodegenerative Diseases (1)  ·  Parkinson Disease (1)

Interventions

pridopidine (10)

Countries

United States (8)  ·  Germany (6)  ·  Canada (5)  ·  France (5)  ·  Italy (5)  ·  Netherlands (5)  ·  Poland (5)  ·  United Kingdom (5)  ·  Austria (3)  ·  Spain (3)  ·  Australia (2)  ·  Belgium (2)  ·  Czechia (2)  ·  Russia (2)  ·  Denmark (1)

Top investigators

Yael Cohen (2)  ·  Merit Cudkowicz, MD (1)

Results publications

PMID 28826192, PMID 30563778, PMID 30572891, PMID 30776019, PMID 31356217, PMID 36811812, PMID 40067755, PMID 40913168, PMID 41406304

NIH funding

2015 (1), 2016 (1)